Endocyte is the patent holder for the PSMA-617 ligand I believe. Recently bought by Novartis. I assume that they feel they have to do this sort of prospective trial, to get NICE approval but it is of no help to you if you are assigned the into the "standard of care" arm. Great if you are assigned into the "trial" arm.
By the way Lu177 PSMA is not a drug, it is a radionucleide ligand, i.e. a radioactive particle emitter that is chemically bound to another chemical which preferentially attaches to prostate tumour cells. The active component of the therapy is the Lu177. The PSMA ligand has no therapeutic effect at all, it is merely a carrier.
It is a pity really that NICE and other regulators cannot use existing data to consider this type of therapy - there is massive data available on "standard therapies" including the fact that they don't, in fact, kill prostate tumours. And there is a growing body of evidence that Lu177 is a well tolerated therapy with modest side effects which can have very beneficial effects, especially if used earlier rather than later, and it does kill tumours, which we know well already due to the experience with other forms of radiotherapy over many decades. The difference between an externally applied energetic particle and that supplied directly to the cell is mostly nothing to do with medicine and plenty to do with physics. Perhaps as most doctors are not physicists they feel they have to reinvent a 50 year old wheel. Meanwhile more papers are published and more people die.